Key Takeaway: Greater Boston Urology has announced the addition of Dr. Akash Sharma and Dr. Rafael Tua-Caraccia to its team. This expansion aims to enhance access to urology and urogynecology services in the region. The move reflects a commitment to improving patient care through the recruitment of skilled professionals.
Price reaction · baseline $2.57 (2026-08-31 close) · hit pre-market · clean, no other RFL news in the window
day 0 close · peak
-5.1%
day 1
-2.3%
day 3
-0.4%
Market Sentiment Analysis
POSITIVE FACTORS
Expansion of urology services in the Greater Boston area.
Addition of experienced professionals to the team.
Improved access to specialized care for patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
11.7%
average across 3 past catalysts
Cash runway
~8 mo
Medium dilution risk
Full Press Release Details
BOSTON--(BUSINESS WIRE)--Greater Boston Urology adds Dr. Akash Sharma and Dr. Rafael Tua-Caraccia, expanding access to urology and urogynecology care across region
Frequently Asked Questions
Who are the new additions to Greater Boston Urology?
Dr. Akash Sharma and Dr. Rafael Tua-Caraccia have joined the team.
What is the purpose of this expansion?
The expansion aims to improve access to urology and urogynecology care.
Where is Greater Boston Urology located?
Greater Boston Urology is based in the Greater Boston area.
What specialties do the new doctors cover?
Dr. Sharma and Dr. Tua-Caraccia specialize in urology and urogynecology.
Biotech snapshot
Cash runway
$30M liquidity · $2M/mo burn
~8 mo
Medium dilution risk
Catalyst track record
+68%
best trade around RFL's most recent catalyst
Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for RFL.